Advertisement
Research Article Free access | 10.1172/JCI115761
Department of Medicine, Duke University Medical Center, Durham, North Carolina 27710.
Find articles by Chaffee, S. in: JCI | PubMed | Google Scholar
Department of Medicine, Duke University Medical Center, Durham, North Carolina 27710.
Find articles by Mary, A. in: JCI | PubMed | Google Scholar
Department of Medicine, Duke University Medical Center, Durham, North Carolina 27710.
Find articles by Stiehm, E. in: JCI | PubMed | Google Scholar
Department of Medicine, Duke University Medical Center, Durham, North Carolina 27710.
Find articles by Girault, D. in: JCI | PubMed | Google Scholar
Department of Medicine, Duke University Medical Center, Durham, North Carolina 27710.
Find articles by Fischer, A. in: JCI | PubMed | Google Scholar
Department of Medicine, Duke University Medical Center, Durham, North Carolina 27710.
Find articles by Hershfield, M. in: JCI | PubMed | Google Scholar
Published May 1, 1992 - More info
Polyethylene glycol (PEG)-modified bovine adenosine deaminase (ADA) is used for replacement therapy of severe combined immunodeficiency disease due to inherited ADA deficiency. We monitored IgG anti-ADA antibody in 17 patients treated by intramuscular injections of PEG-ADA for 1 to greater than 5.5 yr. ELISA-detectable anti-ADA IgG appeared in 10 patients, usually between the third and eighth months of treatment. Anti-ADA levels did not correlate with trough plasma ADA activity, which averaged 1.8-5 times normal blood (erythrocyte) ADA activity, depending on dose (15-60 U/kg per wk). ELISA-detectable anti-ADA antibodies were directed primarily at bovine-specific peptide (rather than PEG-containing) epitopes. Enhanced enzyme clearance, mediated by antibody that directly inhibited native and PEG-modified bovine ADA, and native, but not PEG-modified human ADA, occurred in two patients. In one, tolerance was induced; in the second, twice weekly injections of PEG-ADA compensated for accelerated clearance. We speculate that inhibitory antibodies recognize conserved, relatively PEG-free epitope(s) encompassing the active site, and that in human, but not bovine, ADA a PEG-attachment site "shields" the active site from immune recognition. We conclude that PEG-modification largely prevents the development of high affinity, or high levels of clearing antibodies to bovine ADA, and that PEG-modified human ADA should be further investigated as a possible treatment for ADA deficiency.
Images.